| INTRODUCTION
Proton pump inhibitors (PPIs) have been the treatment of choice for acid-related diseases, such as gastroesophageal reflux disease (GERD), erosive esophagitis and peptic ulcer disease. 1, 2 However, their clinical application has been limited, because PPI inhibition of acid secretion is rather slow; the maximum inhibition occurs only after 2-5 days of standard dosing. Furthermore, PPIs may not adequately control night-time gastric acidity, even when administered at bedtime. 2, 3 In addition, the effect of PPIs may vary significantly among patients, due to genetic polymorphism in drug-metabolising enzymes, particularly cytochrome P450 (CYP) 2C19, which
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metabolises PPIs (except for tenatoprazole). 1, 2 Moreover, according to recommendations, PPIs should be administered in the fasting state, 4 because they must be converted to the active form in the acidic spaces of gastric parietal cells. 2 Unlike PPIs, potassium-competitive acid blockers (P-CABs) reversibly inhibit the gastric H + /K + -ATPase. Because P-CABs are rapidly absorbed and do not require an acidic environment for activation or protonation, they can immediately bind to the H + /K + -ATPase, 4 which leads to prompt, marked inhibition of gastric acid secretion. 5 These advantageous characteristics of P-CABs have made them an attractive alternative to PPIs for treating acid-related diseases. 5, 6 Vonoprazan fumarate (TAKECAB), a P-CAB, was first approved in Japan in December, 2014, for the treatment of gastroduodenal ulcers and reflux esophagitis and as an adjunct to Helicobacter pylori (H. pylori) eradication.
7
YH4808 is a novel P-CAB, currently under clinical drug development (Yuhan Co. Ltd., Seoul, Republic of Korea). In preclinical studies, YH4808 suppressed acid production more potently than esomeprazole, both in vitro and in vivo. For example, in a rat model of histamine-stimulated acid secretion treated with an intravenous injection of YH4808 or PPI, the half-maximum anti-secretory activity required a much lower dose (ED 50 ) of YH4808 than of esomeprazole (0.1 mg/kg vs 0.9 mg/kg respectively). 8 YH4808 showed a favourable safety profile in preclinical toxicity studies in mice, rats, and monkeys; moreover, no adverse effects were observed with doses up to 100 mg/kg/d in rats. In addition, the metabolism of YH4808 involved multiple cytochrome P450 enzymes, so the pharmacokinetics (PK) and pharmacodynamics (PD) of YH4808 would likely be less dependent on CYP2C19 genetic polymorphism than PPIs. Two major metabolites, M3 and M8, were detected readily in animal studies, and it was anticipated that they would also be significant metabolites in humans, although the major pharmacologic activity appeared to arise from the parent drug. An in vitro enzyme assay showed that M8 had negligible inhibitory effects on the H + /K + -ATPase, and M3
had an approximately 2-fold higher IC 50 than the parent drug ( 
nM vs 3.4 nM).
On the basis of this knowledge, we performed the present firstin-human clinical study of YH4808. We aimed to investigate the PK, PD and tolerability profiles of YH4808 after single and multiple oral administrations in healthy volunteers. Furthermore, we compared the acid suppression effect of YH4808 to that of esomeprazole. We also explored the influence of CYP2C19 genetic polymorphism on the PK and PD profiles of YH4808.
2 | ME TH ODS
| Subjects and study design
This study was a randomised, double-blind, placebo-and active comparator-controlled clinical study performed in two parts: a single ascending dose study, and a multiple ascending dose study. We recruited healthy male subjects, 20-45 years of age, with a body weight >50 kg, and within AE20% of ideal body weight. Subjects were enrolled when they showed no abnormality on the medical his- Figure 1 ). In the YH4808 200 mg/d group, after a 7-day washout period at the end of once daily dosing, subjects received YH4808 100 mg twice daily, esomeprazole 40 mg once daily, or placebo ( Figure 1B ; cross-over design).
We performed 24-hours continuous, ambulatory intragastric pH monitoring on Day-1 (baseline), and Day 1 in the single dose study; 
| Genotyping
A blood sample (4 mL) was collected from each subject on Day-1.
DNA was isolated from each sample with the Gentra Puregene DNA Blood samples were centrifuged at 3000 rpm for 10 minutes at inter-day accuracies (relative errors, %) were less than 10.3% and 4.63% respectively. Likewise, intra-and inter-day precision variations (coefficient of variation, CV%) were less than 13.2% and 9.4% respectively.
| Pharmacokinetic analysis
We derived the PK parameters with a noncompartmental pharma- 
| Statistical analysis
The PK and PD parameters were summarised with descriptive statis-
tics. An analysis of variance (ANOVA) was performed to test whether the PK and PD parameters were significantly different among different treatments (ie, different study drugs and different doses) or among individuals with different genotypes. Furthermore, we explored the PK-PD relationship with an E max model, where the primary PD parameter was the percentage of time that the intragastric pH was >4.0 over 24 hours (%Time at pH >4) after the study drug was administered.
The %Time at pH >4 was measured on Day 1 (both the single and multiple-dose studies) and Day 7 (the multiple-dose study), and data from H. pylori-negative subjects were used to explore the PK-PD relation- Of 134 subjects, 123 completed this study (83 and 40 for the single-and multiple-dose studies respectively). Tolerability was assessed in all subjects that received at least a single dose of the study drug (N=126). The PK was assessed in all subjects that received any dose of YH4808 and completed the study as planned (N=79). Intragastric pH was analysed in all subjects that received any of the study drugs, completed the study as planned, and had complete intragastric recordings (ie, >95% of recording time for 24 hours). (N=120; three subjects in the single dose study were excluded due to incomplete recording.) Further detail information on subject participation is presented in Figure S1 . The demographic characteristics of subjects included in the PK and PD analyses were comparable among treatment groups (Table S1 ).
| Intragastric pH
In subjects who were both negative and positive for H. pylori, the % Time of intragastric pH >4 increased significantly in a dose-dependent manner after a single administration of YH4808 (30-800 mg), compared to placebo ( Figure S2 ). In particular, among H. pylori-negative subjects, ≥100 mg YH4808 showed effects similar or superior to the effects of 40 mg esomeprazole in terms of the %Time at pH >4.
After YH4808 100-400 mg had been administered for 7 days, the %Time of intragastric pH >4 increased dose-dependently compared to placebo. However, YH4808 200 mg and 400 mg achieved similar values ( Figure 2 ). At doses ≥200 mg/d, YH4808 maintained intragastric pH >4 for approximately 70% of a 24-hours time period, and the mean %Time at pH >4 increased both during day and night to values greater than those achieved with 40 mg/d esomeprazole (Table 1) .
Despite the administrations of the same total daily dosage, The numbers of subjects in the placebo and esomeprazole groups were N=4 each on Day 1; however, the numbers were 6 and 10 on Day 7 respectively T A B L E 2 Pharmacokinetic parameters of YH4808 after a single and multiple oral administrations Dose group N T max (T max,7d ) (hours) All data represent the meanAESD, except for T max or T max,7d , which represent the median. Metabolic ratio, metabolite AUC/YH4808 AUC.
a AUC 0-12 h,7d.
For both the parent drug and its metabolites, negligible amounts were excreted in the urine. The unchanged parent drug was excreted at amounts too low to quantify precisely; the amounts of M3 and M8 excreted were less than 3% of the dose administered.
A power model analysis of logarithmic transformations of AUC inf for administered doses showed that the systemic exposure to YH4808 increased in a dose-proportional manner in the range of 30-800 mg after a single oral administration. The slopes of the regression lines were 1.15 (95% CI: 1.02-1.28) for AUC inf and 1.00 (0.85-1.15) for C max .
| Relationship between pharmacokinetics, pharmacodynamics, and CYP2C19 genotypes
An E max model adequately described the PK-PD relationship between the YH4808 AUC 0-t and the %Time at pH >4 for 24 hours ( Figure 5A ) in H. pylori-negative subjects. Furthermore, the PK-PD relationship of YH4808 was not altered by the different CYP2C19 genotypes. That is, among the different CYP2C19 genotypes, the differences in AUC were not sufficiently remarkable to alter the PD responses in terms of the %Time at pH >4, even though the dosenormalised AUC 0-t after a single dose was higher in the CYP2C19 PM group than in the CYP2C19 EM group ( Figure 5A ). In contrast, both the PK and the PK-PD relationship of esomeprazole 40 mg were different among the different CYP2C19 genotypes ( Figure 5B and Table 3 ). For example, after a single dose of esomeprazole, subjects with the CYP2C19 EM genotype had a significantly lower AUC 0-t and %Time at pH >4 than subjects with the CYP2C19 IM or PM genotype. Following repeated administrations of YH4808, serum gastrin increased in a dose-dependent manner, compared to the placebo group or the baseline level. However, most of the observed changes in serum gastrin remained within the normal range (0-110 pg/mL; Figure S4 ). There was no clinically significant finding in the clinical laboratory tests, 12-lead ECGs, vital signs or physical examinations during the study.
| Tolerability

| DISCUSSION
The present study was the first clinical study of YH4808 to assess PK, PD, and tolerability in healthy male subjects at both single and multiple-dose administrations. YH4808 exhibited a dose-proportional PK profile, and its pharmacological effect at ≥200 mg/d was comparable to that of esomeprazole at 40 mg/d; ie, YH4808 maintained intragastric pH at >4 for about 70% of a day. YH4808 was well-tolerated, both at a single dose of 30-800 mg and at multiple doses of 100-400 mg for 7 days in healthy subjects.
In this study, we found some potential advantages that YH4808 might have over PPIs, the current standard therapy. First, in direct comparisons between YH4808 and esomeprazole treatments, YH4808 ≥200 mg/d sustained intragastric pH >4 for longer times splitting the YH4808 dose into a twice-daily regimen was significantly more effective than the once-daily regimen for controlling acid secretion at night. Although previous studies showed that a twice-daily PPI dose regimen also improved acid suppression over the once-daily PPI regimen, 13, 14 patients with GERD and healthy subjects continued secreting gastric acid at night; this lack of suppression might lead to an insufficient therapeutic response to PPIs. [13] [14] [15] Consequently, further study will be needed in a patient population to compare therapeutic responses between groups given twice-daily doses of YH4808 or PPIs, based on the control of acid secretion at night. The second advantage of YH4808 was that it increased intragastric pH rapidly after dosing. The AUEC 15 min results showed that, in the initial 2 hours after the first dose, onset of gastric acid suppression appeared within 1 hour. This timing far outpaced esomeprazole, which required >2 hours for the same effect. In addition, YH4808 exerted nearly a maximal inhibitory effect on gastric acidification after a single dose, whereas PPIs only gradually reach maximal effect after repeated administrations. 5 In comparing the %Time at pH >4 over 24 hours, the Day1:Day7 ratios were >0.80 for YH4808 and 0.73 for esomeprazole. This difference may arise from the inherent characteristics of P-CABs, such as rapid absorption and the immediate inhibition of proton pumps. 5 In contrast, the long onset time of PPIs may be due to the several steps required for pharmacologic activity; they must accumulate in the stimulated parietal cell, convert from prodrug to the active form, and then bind covalently to the H + , K + -ATPase. 2 The third advantage of YH4808 was that its PK and PD were less susceptible to specific genetic polymorphism that affect drug metabolising enzymes (ie, CYP2C19), compared to most PPIs, including esomeprazole. 16 Among patients with CYP2C19 PM genotypes, the AUC of YH4808 at a single dose was slightly higher than that of patients with CYP2C19 EM genotypes; nevertheless, the PD responses, in terms of the %Time at pH >4, were similar between these groups. This feature of YH4808 may be derived from its effects on multiple metabolic pathways, including effects on multiple CYPs, as indicated by the diverse metabolites (M3 and M8) that emerged from in vitro experiments with human liver microsomes and various recombinant human CYP enzymes. Indeed, in an exploratory analysis for multiplex genotypes that affected drug metabolising enzymes and transporters, we could not find any clinically significant genotype markers that affected the exposure or efficacy of YH4808 (data not shown).
Similar advantages were found with vonoprazan, the first-marketed P-CAB in Japan. In healthy subjects, 20 mg vonoprazan showed a more sustained effect than PPIs, like 20 mg esomeprazole or 10 mg rabeprazole, in terms of the %Time at pH >4. Moreover, a single dose of vonoprazan produced >80% of the effect achieved after multiple doses. 12 In addition, CYP2C19 polymorphism did not significantly affect either the PK or PD of vonoprazan. 17, 18 These characteristics appeared to contribute to the positive results observed in a non-inferiority trial between vonoprazan at 20 mg/d and lansoprazole at 30 mg/day in patients with erosive esophagitis. 19 Although those two treatments were equally effective at 8 weeks, at 2 weeks, a higher proportion of patients healed in the vonoprazan group than in the lansoprazole group. Moreover, in a subgroup of patients with the CYP2C19 EM genotype, the proportion of patients healed tended to be higher in the vonoprazan group than in the lansoprazole group. Likewise, the favourable pharmacologic aspects of YH4808 may lead to therapeutic advantages in future clinical studies, when it is evaluated in patient populations.
In this study, our results of ambulatory intragastric pH monitoring appeared reliable. Our observations of the mean intragastric pH T A B L E 3 Effect of CYP2C19 genotypes on pharmacokinetics (AUC) and pharmacodynamics (%Time at pH >4) and the %Time at pH >4 after single and multiple doses of esomeprazole 40 mg (active comparator) were similar to previously reported values. 13, [20] [21] [22] [23] [24] In the single dose study, we included H.
pylori-positive subjects (33.7% of subjects) to explore the effects of YH4808 on intragastric pH profiles in the presence and absence of an H. pylori infection. Moreover, it was deemed acceptable to include these patients in the assessments of tolerability and PK up to highest dose level, because the presence of H. pylori would be unlikely to have significant effects on either the tolerability or the single-dose PK. Even H. pylori-positive subjects showed dose-dependent increases in the %Time at pH >4 after a single dose of YH4808, similar to H. pylori-negative subjects. Subsequently, we chose YH4808 doses of 100, 200 and 400 mg/d for the multipledose study, based on the results from the single dose study. In the multiple-dose study, we assessed intragastric pH independent of H.
pylori infections by excluding H. pylori-positive subjects. Moreover, the PD data in H. pylori-positive subjects were excluded from further analyses of the PK-PD relationship.
The observed metabolism of YH4808 to both M3 and M8 was both acute and excessive, which was consistent with findings in previous animal studies. A large proportion of the drug administered was likely to be metabolised via the first-pass effect, which would lead to low YH4808 bioavailability. This assumption was based on the results from nonclinical studies, which showed that the absolute oral bioavailabilities in rat and dog were 9.2% and 4.5%, respectively.
Moreover, a mass balance study, where a radio-labelled drug was administered to rats either intravenously or orally, showed that 98% of the radioactivity was recovered mainly in the metabolites. However, a clinical PK study with both oral and intravenous administrations of radio-labelled drug will be required to confirm the absolute oral bioavailability in humans.
The PK-PD relationship of YH4808, assessed as the %Time at pH >4 vs the drug AUC, was captured with a simple E max model, which represents a classical dose-response profile: %Time at pH >4 over 24 hours = (E max 9AUC)/(EC 50 +AUC). Kirchheiner et al. 25 analysed the relative potency of five PPIs in terms of the mean pH over 24 hours and the dose per day for each PPI, with the following E max model: Mean pH = Baseline mean pH + (E max 9Dose)/(ED50+Dose).
They reported an E max = 3.46, and a baseline mean pH = 3.06, which indicated that at least 11.1-89.2 mg/d of PPIs would be required to achieve a mean pH of 4 over 24 hours. To explore the potency of YH4808 compared to the PPIs from the literature, we obtained corresponding values based on our current data from H. pylori-negative subjects: an ED 50 (95% CI), 78.1 (44.7-111.4) mg/d; a mean pH of baseline, 1.99; and an E max , 3.39. With those values, the minimum required dose derived was 114 mg/d to achieve a mean pH of 4 over 24 hours. This analysis indicated that YH4808 had a similar E max value to that of PPIs, but a higher ED 50 than PPIs. These results may be attributed to the low bioavailability of YH4808.
In the present study, the observed elevation of serum gastrin following multiple dosing of YH4808 could be explained as a physiological feedback response to the suppression of gastric acid secretion. 26, 27 As this observation was similar to that reported in previous clinical studies on PPIs or P-CAB in healthy volunteers, 17, 28, 29 we presumed that this effect was a drug-related change but would not lead to clinically significant adverse effects. However, additional long-term safety assessment should be performed in patients with acid-related diseases in future.
Previous studies reported that intragastric pH profiles were not different between patients with GERD and healthy subjects, 25 between younger and older subjects, or between females and males. 30 Although we can speculate that the intragastric pH profiles in future studies in patients will not differ substantially from the profiles in healthy subjects observed in this study, the present findings may be limited in extrapolations of therapeutic efficacy in patients with GERD.
In conclusion, results from the present study suggested that 
